SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

1. Sarafidis, P.
2. Ferro, C.J.
3. Morales, E.
4. Ortiz, A.
5. Malyszko, J.
6. Hojs, R.
7. Khazim, K.
8. Ekart, R.
9. Valdivielso, J.
10. Fouque, D.
11. London, G.M.
12. Massy, Z.
13. Ruggenenti, P.
14. Porrini, E.
15. Wiecek, A.
16. Zoccali, C.
17. Mallamaci, F.
18. Hornum, M.